Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
Status:
RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of HRS9531 compared with placebo in participants with type 2 diabetes mellitus not adequately controlled with basal insulin, with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study may include up to 23 visits.